Related Experiment Video

Updated: Jan 1, 2026

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

9.5K

Nuclear Factor κB Signaling and Its Related Non-coding RNAs in Cancer Therapy

Xiaomin Liu1, Yang Shao2, Jinbao Zhou2

  • 1School of Environmental and Chemical Engineering, Shanghai University, Shanghai 200444, China; Lab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai 200444, China.

Molecular Therapy. Nucleic Acids
|December 17, 2019
PubMed

Insights

Non-coding RNAs (ncRNAs) regulate the Nuclear factor κB (NF-κB) signaling pathway, which is crucial in cancer development and progression. Targeting ncRNAs offers a promising strategy for novel cancer drug development and treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Nuclear factor κB (NF-κB) is a key transcription factor involved in cell proliferation, inflammation, and cancer.
  • Dysregulated NF-κB signaling is implicated in numerous cancer types, often leading to constitutive activation.
  • NF-κB influences the expression of genes like EGFR, p53, STAT3, and non-coding RNAs (ncRNAs).

Purpose of the Study:

  • To review the regulatory role of ncRNAs (miRNAs and lncRNAs) in NF-κB signaling within the context of cancer.
  • To discuss the clinical significance of ncRNA-mediated regulation of NF-κB in carcinogenesis.
  • To explore the complex interplay between ncRNAs and NF-κB signaling.

Main Methods:

  • Literature review focusing on ncRNA regulation of NF-κB signaling in cancer.
  • Analysis of molecular mechanisms linking ncRNAs, NF-κB, and cancer progression.
  • Discussion of potential therapeutic strategies targeting this pathway.

Main Results:

  • Non-coding RNAs play a significant and intricate role in modulating NF-κB signaling.
  • NF-κB activation can, in turn, influence the expression or status of ncRNAs.
  • The interaction between ncRNAs and NF-κB is crucial in the inflammation-to-carcinogenesis transition.

Conclusions:

  • Targeting NF-κB signaling through ncRNAs presents a promising avenue for cancer drug development.
  • Modulating ncRNA activity offers potential therapeutic strategies for cancer treatment.
  • Understanding the ncRNA-NF-κB axis is vital for advancing cancer therapy.
Keywords:
NF-κBcancer therapynocoding RNA

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.9K
NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells10:57

NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells

Published on: January 12, 2020

11.1K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.4K